NDAINTRATHECALINJECTABLEPriority Review
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRIALT (ziconotide acetate) is a non-opioid analgesic administered via intrathecal injection for severe chronic pain. It is a selective N-type calcium channel blocker that works by reducing neurotransmitter release in the spinal cord. The drug represents an alternative pain management option for patients with cancer pain, post-surgical pain, or chronic pain conditions refractory to other therapies.
$0.099BPart D
LOE ApproachingWith LOE approaching and modest Part D spending (~$99K in 2023), commercial teams face a contraction phase requiring focus on retention and specialty positioning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
OP2C : Prialt® Observatory in Clinical Practice
Started Jul 2020
300 enrolled
Refractory Pain
Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
Started Apr 2008
219 enrolled
Pain ManagementSevere Chronic Pain
Career Relevance
Working on PRIALT offers focused experience in specialty/rare disease commercialization, intrathecal delivery expertise, and healthcare provider relationship management within a niche pain market. However, the LOE-approaching lifecycle limits long-term stability, making this role ideal for professionals seeking deep specialty expertise rather than long-term brand building.
Worked on PRIALT at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.